Aranidipine

Aranidipine

Aranidipine

Antihypertensive drug of the calcium channel blocker class

Aranidipine (INN, trade name Sapresta) is a calcium channel blocker. It is a dihydropyridine derivative with two active metabolites (M-1α and M-1β). It was developed by Maruko Seiyaku and has the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. Its main use is as a hypotensive, reducing blood pressure.[1][2]

Quick Facts Clinical data, AHFS/Drugs.com ...

References

  1. [1]
    "Aranidipine". PubMed. Retrieved 23 December 2018.
  2. [2]
    Gelatsis P (1997). "To Market, to Market – 1996". In Bristol JA, Robertson DW, Doherty AM, Hagmann WK, Plattner JJ, Wong WW, Trainor GL (eds.). Annual Reports in Medicinal Chemistry. San Diego: Academic Press. p. 306. ISBN 978-0-08-058376-1.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Aranidipine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.